NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
16.55
+4.55 (37.92%)
At close: Mar 28, 2025 - Market closed
NTHI Revenue
In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth. NeOnc Technologies Holdings had revenue of $20.00K in the quarter ending December 31, 2024, a decrease of -43.23%.
Revenue (ttm)
$83.00K
Revenue Growth
-8.25%
P/S Ratio
3,737.88
Revenue / Employee
$10,375
Employees
8
Market Cap
310.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
Dec 31, 2022 | 20.00K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 56 minutes ago - NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - GlobeNewsWire
- 4 days ago - NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - GlobeNewsWire
- 6 days ago - NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors - GlobeNewsWire
- 6 days ago - NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors - GlobeNewsWire
- 3 months ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 6 months ago - NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024 - GlobeNewsWire
- 8 months ago - NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewsWire
- 9 months ago - NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation - GlobeNewsWire